Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 4Not yet recruiting 3Active not recruiting 2Completed 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3Lymphoid 1

Conditions

Glioma 2Lymphoma, Follicular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × vorasidenib × Clear all
NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting
24 enrolled
CNS

Brain Neoplasms, Glioma

NCT07215910 2025-10-14

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Alliance for Clinical Trials in Oncology

Phase 3 Not yet recruiting
408 enrolled
CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT06969352 2025-05-13

VICTORIA

Servier (Tianjin) Pharmaceutical Co. LTD.

Not yet recruiting
60 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡